Capital Essence's Investment Blog- 錢途集團 » Page not foundMar 14Comment
Thursday bearish breakdown suggested that short-term overbought correction off the March high of 1883 on the S&P 500 index had evolved into an intermediate-term downtrend with downside target of 1828, which we’ve determined using the trend...
Vanda Pharmaceuticals (VNDA)
Q4 2013 Earnings Call
February 13, 2014 10:00 am ET
James Patrick Kelly - Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with an Overweight rating and $21.00 price target.
In the report, Piper Jaffray noted, “We are initiating,...
In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on Vanda Pharmaceuticals (NASDAQ: VNDA) and maintained a price target of $21.00.
In the report, Piper Jaffray says "We are assuming coverage...
Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA) $16.45. Vanda rising over 26 percent on the session following news that an FDA panel voted overwhelmingly to recommend approval of HETLIOZ for the treatment of Non-24-Hour Disorder...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vanda Pharmaceuticals (VNDA):